Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in CDKN2A
Authors:
- Joan LlachJLJoan Llach
- Paula AguileraPAPaula Aguilera
- Ariadna SánchezASAriadna Sánchez
- Angels GinèsAGAngels Ginès
- Glòria Fernández-EsparrachGFGlòria Fernández-Esparrach
- Guillem SoyGSGuillem Soy
- Oriol SendinoOSOriol Sendino
- Eva VaqueroEVEva Vaquero
- Sabela CarballalSCSabela Carballal
- Fabio AusaniaFAFabio Ausania
- Juan Ramón AyusoJAJuan Ramón Ayuso
- Anna DarnellADAnna Darnell
Open Access
Abstract
Three percent of patients with pancreatic ductal adenocarcinoma (PDAC) present a germline pathogenic variant (GPV) associated with an increased risk of this tumor, CDKN2A being one of the genes associated with the highest risk. There is no clear consensus on the recommendations for surveillance in CDKN2A GPV carriers, although the latest guidelines from the International Cancer of the Pancreas Screening Consortium recommend annual endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) regardless of family history. Our aim is to describe the findings of the PDAC surveillance program in a cohort of healthy CDKN2A GPV heterozygotes. This is an observational analysis of prospectively collected data from all CDKN2A carriers who underwent screening for PDAC at the high-risk digestive cancer clinic of the “Hospital Clínic de Barcelona” between 2013 and 2021. A total of 78 subjects were included. EUS or MRI was performed annually with a median follow-up of 66 months. Up to 17 pancreatic findings were described in 16 (20.5%) individuals under surveillance, although most of them were benign. No significant precursor lesions were identified, but an early PDAC was detected and treated. While better preventive strategies are developed, we believe that annual surveillance with EUS and/or MRI in CDKN2A GPV heterozygotes may be beneficial.Keywords
Funding Information
- Societat Catalana de Digestologia
- Hospital Clinic Barcelona
This publication has 31 references indexed in Scilit:
- Population-Level Analysis of Pancreatic Neuroendocrine Tumors 2 cm or Less in SizeAnnals of Surgical Oncology, 2013
- International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancerGut, 2012
- ATM Mutations in Patients with Hereditary Pancreatic CancerCancer Discovery, 2012
- Review of screening for pancreatic cancer in high risk individualsWorld Journal of Gastroenterology, 2011
- Risk of Pancreatic Cancer in Families With Lynch SyndromeJAMA, 2009
- Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma FamiliesClinical Cancer Research, 2008
- Pancreatic cancer and the FAMMM syndromeFamilial Cancer, 2007
- Geographical Variation in the Penetrance of CDKN2A Mutations for MelanomaJNCI: Journal of the National Cancer Institute, 2002
- Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescenceNature, 2001
- Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis.Gut, 1993